Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience

Switching from Deferasirox Dispersible Tablets to Deferasirox Film-Coated Tablets: Is There an Effect on Ferritin Levels in Children and Adolescents with Transfusion-Dependent Anemia?

“…The most common side effect reported for deferasirox DT is gastrointestinal discomfort, especially abdominal pain, observed in 10%-33% of patients, and up to one-third of patients find the oral suspension unpalatable. 1 , 4 , 10 , 9 , 19 , 20 One of the advantages of the FCT formulation is an expected reduction in these side effects, thus increasing tolerability through ease of intake, and studies have reported adherence and persistence to treatment with FCT to be significantly higher than DT. 9 , 10 , 17 , 19 , 20 The majority of our cohort that received FCT reported greater satisfaction and simpler administration compared with DT.…”

“…Regular blood transfusions, and in some patient groups such as those with thalassemia, increased cell destruction and increased iron absorption as a result of ineffective erythropoiesis, may lead to iron overload. 1 As iron metabolism homeostasis shifts in favor of iron, iron gradually accumulates in heart tissue, liver parenchyma, and in endocrine organs, damaging these systems. Therefore, iron overload monitoring and iron chelation therapy (ICT) have an important role in preventing organ damage and thus improving survival in transfusion-dependent patients, with the treatment being uninterrupted and continuous for optimal success.…”